Compare CTMX & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTMX | CYRX |
|---|---|---|
| Founded | 2008 | 1999 |
| Country | United States | United States |
| Employees | N/A | 1100 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 716.9M | 774.7M |
| IPO Year | 2015 | 2008 |
| Metric | CTMX | CYRX |
|---|---|---|
| Price | $3.26 | $16.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 8 |
| Target Price | $12.10 | ★ $13.31 |
| AVG Volume (30 Days) | ★ 2.5M | 487.3K |
| Earning Date | 05-08-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 156.22 |
| EPS | ★ N/A | N/A |
| Revenue | $76,201,000.00 | ★ $176,177,000.00 |
| Revenue This Year | N/A | $11.06 |
| Revenue Next Year | $7.61 | $8.45 |
| P/E Ratio | $22.58 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.90 | $7.61 |
| 52 Week High | $8.21 | $17.20 |
| Indicator | CTMX | CYRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.01 | 56.03 |
| Support Level | $3.01 | $14.55 |
| Resistance Level | $3.57 | $16.87 |
| Average True Range (ATR) | 0.15 | 0.63 |
| MACD | 0.00 | 0.11 |
| Stochastic Oscillator | 44.71 | 67.69 |
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.